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As a foreign protein composed of 58 amino acid
residues with a molecular weight of 6512 d, aprotinin is
capable of inducing an immune response.3 The reactive-
site region of the molecule represents the main
immunogenic epitope.4 The frequency of severe allergic
and pseudoallergic shock reactions after systemic re-
exposure is estimated to be about 2% to 3%.5
Aprotinin is also contained in biologic tissue sealants,
which have been commercially available in Europe
since the late 1970s and in the United States since 1998.
After the fibrinogen and thrombin components are
mixed, a fibrin clot forms, the lysis of which is retarded
by a small dose of aprotinin.6 Their efficacy as a hemo-
static agent has been demonstrated in many surgical and
nonsurgical disciplines.7-9 Reports of only a few cases
of shock reactions induced by the aprotinin component
have so far been published.10-12
Anaphylactic reactions are caused by mediator
release from mast cells as the result of the cross-bind-
A protinin is a polyvalent proteinase inhibitor isolatedfrom cattle lungs and has been in clinical use since
the early 1960s. Its major indication was initially the
treatment of acute pancreatitis. Today aprotinin has
found its major application in cardiac operations for its
well-documented beneficial effects on perioperative
blood loss, transfusion requirements, and probably the
inflammatory response to cardiopulmonary bypass.1,2
Background: In cardiac operations, aprotinin therapy is used either local-
ly as a component of commercially available fibrin tissue adhesives,
intravenously, or combined. Our aim was to examine the formation of
aprotinin-specific antibodies with regard to the application mode.
Methods: Sera of 150 patients who had undergone cardiac operations and
were receiving aprotinin therapy for the first time were sampled before
the operation and at medians of 3.5 and 13.3 months after the operation.
Aprotinin-specific IgG including all subgroups and aprotinin-specific
IgE were analyzed. Aprotinin was given locally (as contained in fibrin
sealant; n = 45; median dose, 6000 KIU), intravenously (n = 46; 2.000 ·
106 KIU), and combined (n = 59; 2.012 · 106 KIU). Results: At 3.5
months, the prevalence of aprotinin-specific IgG antibodies was 33%
(15/45 patients) after local, 28% (13/46 patients) after intravenous, and
69% (41/59 patients) after combined exposure (P = .0001). At 13.3
months, the prevalence of aprotinin-specific IgG antibodies was 10%
(4/41 patients) after local, 31% (13/42 patients) after intravenous, and
49% (28/57 patients) after combined exposure. Total aprotinin dose was
similar in patients who were antibody positive and negative. Before the
operation, no aprotinin-specific antibodies were detected. Aprotinin-
specific IgE were not found after the operation. Conclusion: Local apro-
tinin contact induces a specific immune response and reinforces that of
intravenous exposure. The antibody spectrum is identical to the immune
response induced by intravenous exposure. Any exposure should be doc-
umented. For use in cardiac operations as a hemostyptic, the necessity
itself and alternatives for aprotinin as a stabilizing agent merit consid-
eration. (J Thorac Cardiovasc Surg 1999;118:348-53)
Albertus M. Scheule, MD
Wolfram Beierlein, MD
Hans P. Wendel, PhD
Michael J. Jurmann, MD
Friedrich S. Eckstein, MD
Gerhard Ziemer, MD
From the Department of Surgery, Division of Thoracic, Cardiac and
Vascular Surgery, Tübingen University Hospital, Germany.
Received for publication Sept 8, 1998; revisions requested Nov 6,
1998; revisions received March 8, 1999; accepted for publication
April 6, 1999.
Address for reprints: Gerhard Ziemer, MD, Department of Surgery,
Division of Thoracic, Cardiac and Vascular Surgery, Tübingen
University Hospital, Hoppe-Seyler Straße 3, D-72076 Tübingen,
Germany.
Copyright © 1999 by Mosby, Inc.
0022-5223/99 $8.00 + 0 12/1/99092
APROTININ IN FIBRIN TISSUE ADHESIVES INDUCES SPECIFIC ANTIBODY RESPONSE AND
INCREASES ANTIBODY RESPONSE OF HIGH-DOSE INTRAVENOUS APPLICATION 
The Journal of Thoracic and
Cardiovascular Surgery
Volume 118, Number 2
Scheule et al   349
ing of 2 surface-bound IgEs.13 IgGs can also trigger
reactions clinically indistinguishable from anaphylaxis
by involvement of the complement system.14,15
The different antibody types are formed by plasma
cells after stimulation of different populations of T-
helper (TH) lymphocytes by antigen-presenting cells:
TH0-lymphocytes induce a primary response with a
broad spectrum of immunoglobulins. At repeated expo-
sures, TH1-lymphocytes may induce the formation of
IgG1 and IgG3, whereas TH2-lymphocytes may generate
IgG4 and IgE.16,17 Although the presence of specific
IgE or IgG antibodies alone does not necessarily lead to
hypersensitivity reactions,18 their measurement in the
serum is an important tool in clinical practice.
However, the serologic findings require clinical corre-
lates such as characteristic symptoms or an evocative
history to justify the diagnosis of sensitization to a spe-
cific allergen. Re-exposure tests such as skin tests are
widely used for this purpose. For aprotinin, their relia-
bility is questionable.5
Most shock incidents on repeated aprotinin applica-
tion seem to be immune mediated, implying that pre-
ceding exposures must have induced aprotinin-specific
antibodies and allergic sensitization. The literature con-
tains many cases that occurred after only 1 previous
contact with the drug.5,19,20 Former studies have
revealed a prevalence of specific antibodies in about
50% of patients who had received 1 intravenous high
dose of aprotinin.21,22
In cardiac operations, aprotinin is used either locally
as a component of commercially available fibrin tissue
adhesives, intravenously, or in combination of both.
Therefore it was our aim to examine whether the
immunostimulatory potency of a first-time contact
depends on the route of administration.
Patients, methods, and analyses
Patients. Patients undergoing cardiac operations and
receiving first time aprotinin were eligible for the study
group. A complete history focusing on allergies was obtained
from each patient. Informed consent was obtained from each
patient; all patients were informed in writing about the results
and implications.
Methods. Intraoperatively, patients received either a com-
mercially available fibrin sealant (Tissucol Duo S; Immuno,
Vienna, Austria), a saline aprotinin solution (Trasylol; Bayer,
Leverkusen, Germany), or a combination of both (Table I).
Tissucol consists of 2 components: a plasma fraction (con-
taining 70-110 mg fibrinogen, 2-9 mg plasma fibronectin, 10-
50 units coagulation factor VIII, 0.02-0.08 mg plasminogen
[all human], and 3000 KIU/mL bovine aprotinin) and a
thrombin fraction (containing 500 U human thrombin and
5.88 mg/mL calcium chloride). Trasylol contains 10,000 KIU
aprotinin per milliliter isotonic sodium chloride solution. 
Neither high-dose intravenous aprotinin nor fibrin tissue
adhesives are routinely used in our division. The decision to
use 1 or both was only made intraoperatively because of sur-
gical necessity. The aprotinin dosages in groups are present-
ed in Table I.
Serum samples were obtained before the operation, at
approximately 4 months (median, 3.5 months; interquartile
range [IQR], 3.2-3.9 months) and 13 months (median, 13.3
months; IQR, 11.7-14.7 months) after the operation. The
samples were centrifuged for 15 minutes at 10°C with 1200g
and stored at –20°C until the in vitro anti-aprotinin–specific
antibody screening tests were performed. 
Antibody detection. Serologic analyses comprised an
automatized fluorescence enzyme immunoassay (UniCAP
System; Pharmacia & Upjohn, Uppsala, Sweden) for the
detection of aprotinin-specific IgE and a standard enzyme-
linked immunosorbent assay technique for quantitative detec-
tion of aprotinin-specific total IgG (tIgG) as previously de-
scribed.24 The same enzyme-linked immunosorbent assay
technique was used for specification of IgG-subgroups 1 to
4 (mouse anti-human IgG1,2,3,4 monoclonal antibody;
Pharmingen, San Diego, Calif; diluted 1:1000; serum dilu-
tion, 1:100) but, in a semiquantitative fashion, currently lack-
ing established standards.
Statistics. Intergroup differences of tIgG prevalence and fre-
quency of allergies were examined with the use of the c 2 test.
McNemar’s test (2-tailed) was used to compare prevalence
Table I. Operations and aprotinin dosages
Operations: percent (total) Median aprotinin dosage* (IQR)
CABG + Valve Trasylol, Tissucol,
Group n CABG IMA IMA replacement Combined† Other‡ intravenous local
Local 45 13.3 (6) 4.4 (2) 55.6 (25) 13.3 (6) 6.7 (3) 6.7 (3) 0 3,572 (3,168-5,680)
Intravenous 46 4.3 (2) 2.2 (1) 41.3 (19) 52.2 (24) 0 0 1.08· 106 (1.01-1.18· 106) 0
Combined 59 5.1 (3) 3.4 (2) 72.9 (43) 10.2 (6) 8.5 (5) 0 1.11· 106 (1.03-1.25· 106) 5,906 (3,318-9,088)
CABG, Coronary artery bypass grafting; IMA, internal mammary artery.
*KIU/m2BSA (Kallikrein inhibiting units per square meter of body surface area).
†CABG + valve. 
‡Atrial septum defect, aneurysmectomy, aorta ascendens replacement.
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within groups. Time-dependent drop in tIgG concentrations
was examined with the nonparametric Wilcoxon matched pairs
signed rank test. IgG values that were equal (or undetectable)
at both examinations did not yield any relevant differences and
were thus excluded from the test. The influence of aprotinin
amount applied per square meter of body surface area on IgG
formation as assessed by a positive screening test (IgG > 10
mg/L) was examined by logistic regression analysis with the
statistical package JMP (SAS, Inc, Cary, NC). U-test was
applied to examine differences of aprotinin-specific IgG levels
in allergic and nonallergic patients. Not normally distributed
values are presented as medians with interquartile ranges.23
Results
One hundred fifty patients were selected consecu-
tively from adult patients who had undergone operation
electively for acquired heart disease in our division
between August 1995 and July 1996. Twenty-two fur-
ther patients were not eligible because aprotinin-spe-
cific serum IgG was present before the operation, and
11 additional patients were not eligible because of doc-
umented former aprotinin contact. 
Seven patients with negative screening tests before
the operation and who received no aprotinin therapy
were reexamined after 3.8 months (IQR, 3.5-4.3
months). No aprotinin-specific antibodies were detect-
ed in this group. 
Seven of the 150 patients underwent cardiac reoper-
ations without previous application of fibrin sealant or
infusion of aprotinin. Table I details the operations and
median aprotinin doses; Table II details the demo-
graphic data and allergic history. 
The 150 preoperative sera were negative for all apro-
tinin-specific antibodies tested.
Each application mode of aprotinin was capable of
inducing a specific antibody response after a first and
unique application. Within the 3 groups, the aprotinin
amounts that were standardized according to the body
surface area did not differ significantly between patients
who were deemed antibody positive and negative (local,
P = .36; intravenous, P = .52; combined, P = .60; JMP). 
The prevalence of detectable tIgG levels was highest
in the group with combined exposure (approximately
70%) and significantly lower in the groups with local
or intravenous contact (approximately 30% each)
approximately 4 months after the operation (P = .0001;
c
2 test). After 13 months, the prevalence decreased sig-
nificantly after local and combined contact but
remained stable after intravenous contact (Table III;
Fig 1). Most seroconverters in both directions were
observed in the combined group (Table IV). 
Except for 3 patients, all patients who had detectable
levels of aprotinin-specific antibodies at 4 months had
significantly lower levels after 1 year (Table IV).
Patients with aprotinin-specific tIgG levels higher than
the third quartile of positives had received aprotinin
doses that did not differ significantly from those of
patients with positive levels below (P = .1 at 3.5
months and P = .24 at 13.3 months; JMP).
The spectrum of aprotinin-specific IgG subgroups
comprised mainly IgG1 and IgG4. In nearly all patients,
IgG1 contributed to tIgG. The contribution of IgG4 to
tIgG was lower, but its activity increased at approxi-
mately 13 months. Nearly all sera containing IgG4 were
also positive for IgG1. IgG2 and IgG3, which played a
minor role, were detectable at 4 months after combined
application, but only in a few patients and with very
weak activity. IgE was not found in any patient. 
Table II. Demographic data and allergic history
No. of allergic diathesis* (%)
Age No. of male Allergic patients: Insect 
Group n (yr ± SD) patients (%) percent (total) Food Drugs Inhalative Contact venom
Local 45 60 ± 16 60.0 (27) 31.1 (14) 14.3 (2/14) 50.0 (7/14) 14.3 (2/14) 21.4 (3/14) 7.1 (1/14)
Intravenous 46 62 ± 8 67.4 (31) 34.8 (16) 6.3 (1/16) 50.0 (8/16) 12.5 (2/16) 37.5 (6/16) 0
Combined 59 60 ± 11 76.3 (45) 27.1 (16) 12.5 (2/16) 43.8 (7/16) 12.5 (2/16) 25.0 (4/16) 12.5 (2/16)
Total 150 60 ± 12 68.7 (103) 30.7 (46) 10.9 (5/46) 47.8 (22/46) 13.0 (6/46) 28.3 (13/46) 6.5 (3/46)
*Specific allergies listed multiple times.
Table III. Prevalence of aprotinin-specific IgG over time
Patients positive* (%)
Group 3.5 Mo 13.3 Mo P value†
Local 33.3 9.8 .005
Intravenous 26.1 31.0 >.1
Combined 69.5‡ 49.1‡ .03
Whole group 45.3 32.1 .002
*See Fig 1 for the number of patients.
†McNemar, 2-tailed.
‡Combined versus local and intravenous: 3.5 months, P = .0001; 13.3 months,
P = .0004 ( c 2 test).
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The incidence of aprotinin-specific antibodies in the
46 allergic patients was 43.5% (20/46 patients) within
the observation period, which was nearly the same per-
centage as in nonallergic patients (46.2%; 48/104
patients). At both examinations aprotinin-specific tIgG
levels did not differ significantly between allergic and
nonallergic patients (P > .2; U-test). The median posi-
tive levels were 63 mg/L (IQR, 18-124 mg/L) in aller-
gic patients and 78 mg/L (IQR, 29-186 mg/L) in non-
allergic patients at 4 months and 36 mg/L (IQR, 19-58
mg/L) versus 26 mg/L (IQR, 19-50 mg/L) at 13
months. There were 42.9% of tIgG positive patients
(6/14 patients) among the allergic patients who had
received local aprotinin application, 31.3% tIgG posi-
tive patients (5/16 patients) among those with intra-
venous application, and 56.3% tIgG positive patients
(9/16 patients) among those with combined applica-
tion. Most tIgG-positive atopic patients were allergic
to drugs (60.0%; 12/20 patients); but compared with
the group of antibody-negative allergic patients
(38.5%; 10/26 patients), this preponderance of drug
allergies was statistically not significant (P = .15; c 2
test). 
Comments
Study design. This prospective study examined the
immune response induced by a single and first apro-
tinin exposure through fibrin tissue adhesive, infusion,
or both. The design reflected the immune status that an
aprotinin re-exposure would encounter after approxi-
mately 4 and 13 months. Because there is a certain risk
of shock reactions on any re-exposure, even on skin
tests, we had considerable ethical concerns about per-
forming exposure tests without an imperative clinical
need. Additionally, skin tests could have influenced the
immune response in our patients. We therefore deliber-
ately did not perform these tests. 
We combined our data with the features of aprotinin-
induced shock reactions known from literature to
deduce recommendations for clinical practice. 
Fig 1. Prevalence of total aprotinin-specific IgG at 3.5 and 13.3 months, depending on application mode.
Table IV. Aprotinin-specific tIgG concentrations versus time after exposure
Median aprotinin-specific tIgG† (IQR) Seroconverters‡ (n)
Group* 3.5 Mo 13.3 Mo Positive to negative Negative to positive P value§
Local 34.1 (20.7-61.9) 45.0 (22.4-65.2) 9 0 .01
Intravenous 165.6 (96.5-321.6) 47.1 (30.6-70.9) 3 4 .01
Combined 78.4 (19.8-186.3) 25.2 (14.6-38.4) 14 3 <.0001
Whole group 77.5 (21.9-177.0) 26.3 (18.8-52.1) 26 7 <.0001
*See Fig 1 for number of patients.
†Measured as milligrams per liter in patients with detectable levels.
‡3.5 vs 13.3 months.
§Wilcoxon matched pairs signed rank test.
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Significance of antibodies. Immune-mediated shock
reactions on re-exposure to proteins are most common-
ly induced by specific antibodies of the subtypes IgE
and IgG. The pathophysiologic condition underlying
true anaphylactic reactions is IgE triggered.13 The fact
that we found IgE in none of the patients might reflect
the rarity of such reactions on aprotinin re-exposure.
However, we were surprised by this finding because in
a former study we found a 14.3% incidence of IgE in
children within 6 weeks after first-time exposure to fib-
rin sealant.24 The absence of IgE in our adult patients
may be that the 4-month interval between aprotinin
exposure and blood sampling is too long to detect an
IgE response. Immunoregulatory processes may be dif-
ferent in children and adults, because full immuno-
competence matures within the first years of life.17
The role of antigen-specific IgG for anaphylactic and
anaphylactoid reactions is still the subject of controver-
sy. Its significance may depend on the serum level, the
distribution of its subclasses, or the distribution of IgG
and IgE. 
According to Dietrich and colleagues,25 a patient’s
reactivity might depend on a high level of aprotinin-spe-
cific IgG. The significant decrease of total IgG levels in
our whole group over 1 year seems to be consistent with
the decreasing risk of shock reactions.5 The absence of
IgE in all patients at 4 months is also consistent with
this conception. However, the high prevalence of apro-
tinin-specific IgG at both examinations is in contrast to
the rareness of anaphylactic reactions on re-exposure.
This finding renders an association of IgG antibody
presence and shock reactions rather uncertain. Although
we had patients with high anti–aprotinin IgG levels, our
data do not have the potential to confirm or disprove the
thesis of Dietrich and colleagues, because we did not re-
expose our patients for the reasons mentioned earlier. 
According to van der Zee and Aalberse,26 the ana-
phylactic significance of IgG may depend on the
“homocytotropic activity” of the IgG4 subclass (ie, its
capability of binding to mast cells and thereby acting as
an anaphylactic antibody). Our results show an in-
crease of aprotinin-specific IgG4 over 1 year. This is
contrary to the clinical observation of a risk decreasing
with time. The phenomenon of rising IgG4-levels is
therefore possibly an in vitro artifact by secondary
IgG4 antibodies directed against aprotinin-specific IgG
(anti-idiotypic antibodies).27
In a case control study on patients with acute reac-
tions to protamine, Weiss and colleagues28 found an
increased risk associated with the presence of both pro-
tamine-specific IgG and IgE. The relative risk associat-
ed with IgE was higher than that associated with IgG.
Although protamine is a small molecular-weight for-
eign protein like aprotinin, these data must not be read-
ily transferable to aprotinin.
Role of application mode. Any aprotinin exposure
may induce a systemic immune response in adult
patients. Local aprotinin additional to intravenous
application has an over-additive effect on the incidence
of aprotinin-specific IgG.
This phenomenon may be due to different pharmaco-
kinetic properties of the application modes. After the
systemic administration, the immune system is over-
whelmed by high antigen doses for a short time (elim-
ination half time, approximately 2 hours).3 In contrast,
a fibrin sealant clot stabilized by aprotinin stays stable
for up to 4 weeks6 and may thereby act as a temporary
antigen-presenting deposit for the immunocompetent
cells infiltrating the wound and the fibrin clot during
the healing process.
Time course of immune response. The decrease in
the combined group was nearly the same compared
with that of the local group after 1 year. Considering
the stability in the intravenous group, one may hypo-
thesize that the decrease in the combined group is the
effect of 2 superposed kinetics being each characteris-
tic of a different immune compartment stimulated by
the local and the intravenous application, respectively. 
The decrease of aprotinin-specific tIgG reflects the
absent reboostering effect in lack of further contacts
with the immunogen. Although Table IV presents a
higher median tIgG level after local exposure at 1 year,
the individual levels decreased also in these 4 patients.
Weipert and colleagues22 showed that aprotinin-specif-
ic antibodies may persist even up to 4 years after a sin-
gle intravenous high dose during cardiac operations.
In a Medline search of literature from 1963 to 1998,
we found 50 papers presenting 107 cases of shock reac-
tions to aprotinin: 70 patients were pre-exposed
(65.4%); 44 reports mentioned the re-exposure inter-
val, which was less than 3 months in 30 cases (68.2%).
Combined with our data, this underlines that immuno-
reactivity to aprotinin depends on time. Thus the re-
exposure interval is an important determinant for the
risk of shock reactions to aprotinin.
Allergic history. Our patients’ histories of allergies did
not predict the immune response to aprotinin. This can be
attributed to the number of patients being too small for
reliable epidemiologic calculations. Large clinical studies
on anesthetic drugs revealed atopy and female gender as
risk factors for IgE-mediated reactions.29
Clinical impact and conclusion. This study demon-
strates that a single local contact with aprotinin by
commercially available fibrin tissue adhesives is capa-
ble to induce an immune response in adult cardiosurgi-
cal patients. Although the local dose represented only
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permills of the intravenous dose, the antibody spectrum
was identical with that induced by a single intravenous
high-dose exposure. 
The detectable antibody response to aprotinin weak-
ens with time. This corresponds with the clinical obser-
vation that the incidence of shock reactions to aprotinin
decreases after 6 months. As a measure of precaution,
aprotinin administration in any form should be avoided
within the first months after previous exposure. A
patient’s history of allergies is not indicative of the
aprotinin-specific immune response.
In clinical practice, the use of commercially available
fibrin tissue adhesives is commonly not documented.
Before any aprotinin use, clinical evaluation should
include the search for possible recent intravenous or local
aprotinin exposures. To facilitate this search, we recom-
mend a careful documentation of any aprotinin use. 
Considering the potency to induce aprotinin-specific
antibodies, it becomes questionable whether aprotinin
should be added to fibrin tissue adhesives for all appli-
cations. The necessity itself and alternatives for apro-
tinin as a stabilizing agent merit detailed consideration.
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